# Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

> **NCT03938246** · PHASE2 · COMPLETED · sponsor: **Sagimet Biosciences Inc.** · enrollment: 142 (actual)

## Conditions studied

- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

## Interventions

- **DRUG:** TVB-2640 25 mg (US)
- **DRUG:** TVB-2640 50 mg (US)
- **DRUG:** Placebo (US)
- **DRUG:** TVB-2640 50 mg (China)
- **DRUG:** Placebo (China)
- **DRUG:** TVB-2640 75 mg (US)

## Key facts

- **NCT ID:** NCT03938246
- **Lead sponsor:** Sagimet Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-22
- **Primary completion:** 2021-10-02
- **Final completion:** 2021-10-02
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03938246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03938246, "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03938246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*